Related Experiment Video

Updated: Jun 27, 2026

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
05:25

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft

Published on: September 15, 2023

Pre-operative atorvastatin therapy to decrease the systemic inflammatory response after coronary artery bypass

Y Dereli1, E Ege, S Kurban

  • 1Department of Cardiovascular Surgery, Meram Medical School, Selçuk University, Konya, Turkey.

The Journal of International Medical Research
|December 20, 2008
PubMed

Insights

Pre-operative atorvastatin significantly reduced inflammatory markers like C-reactive protein and interleukin-6 in patients undergoing coronary artery bypass grafting (CABG). This suggests atorvastatin may help prevent systemic inflammatory response syndrome (SIRS) after CABG surgery.

Area of Science:

  • Cardiology
  • Pharmacology
  • Immunology

Background:

  • Systemic inflammatory response syndrome (SIRS) is a common complication following coronary artery bypass grafting (CABG).
  • Statins, like atorvastatin, possess anti-inflammatory properties that may mitigate SIRS.
  • Pre-operative statin use in CABG patients warrants further investigation for its impact on inflammatory markers.

Purpose of the Study:

  • To evaluate the effect of pre-operative atorvastatin on inflammatory markers and SIRS in patients undergoing elective CABG.
  • To compare post-operative inflammatory responses between patients receiving pre-operative atorvastatin and those who did not.

Main Methods:

  • A prospective study involving 40 patients undergoing elective CABG.
  • Patients were divided into two groups: Group I (LDL cholesterol ≥ 100 mg/dL) received atorvastatin 20 mg/day for ≥ 15 days pre-operatively; Group II (LDL cholesterol < 100 mg/dL) received no antihyperlipidemic agents.
  • Blood samples were collected pre-operatively and 24 hours post-operatively to measure high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6).

Main Results:

  • No significant differences in demographic, pre-operative, or operative parameters between groups.
  • Post-operatively, Group I showed significantly lower median hs-CRP and mean IL-6 levels compared to Group II.
  • Group I patients had a shorter intensive care unit (ICU) stay, with no other significant differences in post-operative outcomes.

Conclusions:

  • Pre-operative atorvastatin administration in elective CABG patients effectively reduces post-operative inflammation.
  • Atorvastatin may play a role in preventing SIRS following CABG.
  • Further research is recommended to confirm the clinical benefits of pre-operative statin therapy in CABG patients.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...